OMER241220C2000
- 5.50
- 0.000.00%
Omeros Newsroom
Replimune REPL +35% BLA Submission; Omeros OMER +41% BLA Update
Natural Grocers By Vitamin Cottage, Elastic, Matthews International, Gap And Other Big Stocks Moving Higher On Friday
Express News | Omeros Corp - FDA Requests Additional Sensitivity Analyses for Sap
Express News | Omeros Corp - Independent Expert Statistical Group to Conduct Analyses
Express News | Omeros Corp - Receives FDA Response on Revised Sap for Narsoplimab Bla
Express News | Omeros Corporation Provides Update on Progress Toward Bla Resubmission
While Institutions Invested in Omeros Corporation (NASDAQ:OMER) Benefited From Last Week's 54% Gain, Retail Investors Stood to Gain the Most
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application
Omeros Up Over 49%, On Pace for Largest Percent Increase Since February 2023 -- Data Talk
Express News | Cantor Fitzgerald Reiterates Neutral on Omeros
Rodman & Renshaw Maintains Omeros(OMER.US) With Buy Rating, Cuts Target Price to $9
Express News | Rodman & Renshaw Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $9
Needham Maintains Omeros(OMER.US) With Hold Rating
Omeros Analyst Ratings
Omeros (OMER) Gets a Hold From Needham
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript Summary
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
Omeros | 10-Q: Q3 2024 Earnings Report
Omeros | 8-K: Omeros Corporation Reports Third Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET
Omeros Expects Sept FDA Presubmission Meeting and Minor Revisions to Plan Should Clear Way to Resubmit BLA for Narsoplimab in TA-TMA